Home – Page 50 – The Cancer Letter

Issue 13 - Mar 31, 2017

TCL43-13 (303 downloads)

Conversation with the Cancer Letter
Amy Abernethy: I want health IT companies to have an honest conversation about data sharing
It’s fair to say that eight years ago, when the Obama administration infused the economy with $800 billion in stimulus funding, policymakers likely did not expect the health information technology industry to evolve into fiefdoms guarded by legions of lawyers and walls of proprietary code.
Genentech’s rituximab SC received unanimous ODAC approval recommendation
The FDA Oncologic Drugs Advisory Committee March 29 unanimously recommended approval of a lymphoma treatment, to be administered via subcutaneous injection.
In Brief
- Carlo Croce to receive 2017 AACR Margaret Foti Award for leadership, achievements in research
- Roger Lo to receive AACR-Waun Ki Hong award for outstanding achievement in cancer research
- Bezos family donates $35M to Fred Hutchinson
- Cancer death rates continue to decrease
- NCCN publishes Radiation Therapy Compendium
- NCCN Foundation awards grants to four young investigators
- Friends launches ProgressForPatients.org
- Health coalition forms National Lung Cancer Roundtable
- Columbia, New York-Presbyterian, FNIH enter research collaboration
- The Mikey Czech Foundation Contributes $1 Million To DIPG Research at Dana-Farber
- Jeffrey Ravetch gets Ross Prize in Molecular Medicine
- Alan Bernstein awarded Friesen prize
Drugs and Targets
- FDA approves AstraZeneca’s Tagrisso for EGFR mutation-positive NSCLC
- FDA approves niraparib for epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Gamida Cell receives EMA orphan drug designation for NiCord
- Cota, Novartis form collaboration to advance real-world evidence in breast cancer therapies
- Novartis CAR-T cell therapy for pediatric r/r B-cell ALL gets FDA Priority Review
- BMS, Foundation Medicine form collaboration to identify predictive biomarkers across tumor types, immunotherapy agents
- AbbVie, M2Gen announce collaboration for the ORIEN Avatar Research Program

Issue 12 - Mar 24, 2017

TCL43-12 (304 downloads)

Doug Lowy: We should continue to focus on the FY17 appropriation
The White House budget blueprint to slash NIH funding by 18.3 percent in fiscal 2018 is just a proposal, NCI Acting Director Douglas Lowy said at the meeting of the Board of Scientific Advisors March 21.
Conversation with the Cancer Letter
Rick Klausner: This is a profoundly disturbing statement about dramatically de-prioritizing research, science, and biomedical research
President’s Donald Trump’s budget proposal should be treated as a genuine, credible threat to science, said Richard Klausner, a biotechnology entrepreneur who led NCI through the years of the doubling of the NIH budget.
Conversation with the Cancer Letter
Fran Visco: We should be partners on every level, not just when the NIH budget is threatened
Scientists and patient advocates have largely overlapping agendas, but, ultimately, their agendas diverge, said Fran Visco, president of the National Breast Cancer Coalition, the organization that ushered in a new era in the politics of cancer research and delivery of care.
In Brief
- Levine Cancer Institute launches first mobile lung CT unit in the U.S.
- St. Jude names research tower for Donald Pinkel
- Robert Wechsler-Reya named RCIGM’s program director for neuro-oncology
- Lauren Lawrence named vice president of Karmanos Cancer Network
- Patil named first-ever Chief Data Officer of the Year by CDO Club
- Sanofi Genzyme extends Multiple Myeloma Journey Partners Program to cities nationwide
- NCCN Foundation Board names new leadership
Drugs and Targets
- Bavencio receives accelerated approval for Merkel cell carcinoma

Issue 11 - Mar 17, 2017

TCL43-11 (2389 downloads)

Trump’s proposed 2018 budget launches a surprise attack on NIH
FDA may have escaped the devastating cuts in President Trump’s first budget proposal, while NIH ended up taking the brunt of its fury.
White House “vision” would cripple NIH
Dear Reader,
This issue of The Cancer Letter is free. Send it to your colleagues.
Conversation with the Cancer Letter
John Porter: If you want to make America great, you don’t take America’s worldwide scientific lead and cut it
As former chairman of the Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, then-Rep. John Porter (R-IL) oversaw the doubling of the NIH budget over five years.
Conversation with the Cancer Letter
Nancy Davidson: This is the time for investment, not for retreat
First, Congress should follow through on increasing the NIH budget by $2 billion in fiscal 2017, said Nancy Davidson, president of the American Association for Cancer Research.
Second, the House and the Senate should craft appropriations bills that will provide robust, sustainable, and predictable increases for fiscal 2018, said Davidson, executive director and president at Seattle Cancer Care Alliance, senior vice president and director of the Clinical Oncology Division at Fred Hutchinson Cancer Research Center, and professor and Head, Division of Medical Oncology at the University of Washington School of Medicine.
Conversation with the Cancer Letter
Ellen Sigal: This is not a grasstops issue anymore, this is really grassroots
Over decades, Ellen Sigal has emerged as a Washington insider in oncology, someone who has the ability to convene key players in academia, industry and government.
Conversation with the Cancer Letter
Blase Polite: This was put together by folks who have no sense of how research is done
If Congress follows the fiscal 2018 budget priorities outlined by the White House, the United States will lose its standing as the powerhouse of biomedical research, said Blase Polite, chair of the American Society of Clinical Oncology Government Relations Committee.
Conversation with the Cancer Letter
Patricia Goldsmith: This is the “Moonstab,” or, maybe, the “Moonshaft”
Coupled with the repeal of the Affordable Care Act, the administration’s proposed cuts to the NIH budget would be devastating for cancer patients, said Patricia Goldsmith, CEO of CancerCare, an organization that provide counseling, support groups, education, and financial assistance.
“Duplicity” at NIH?
White House spokesman Sean Spicer says the cut isn’t really a cut
White House spokesman Sean Spicer said the cuts proposed by the administration will help eliminate inefficiency and duplication at NIH. At a White House press briefing March 16, Spicer was asked to justify his boss’s proposal to gut biomedical research funding.
Beth Caldwell: People like me will die because of these cuts
Beth Caldwell, a patient with metastatic neuroendocrine breast cancer, has more to lose than anyone else in the controversy over President Donald Trump’s proposed cuts to the NIH budget.
In Brief
- Marshall Hicks named interim president of MD Anderson Cancer Center
- Stupp named associate director, strategic initiatives at Lurie Cancer Center
- City of Hope vice provost to focus on faculty growth initiatives
- Nichols named LLS chief medical officer
- Penson named chair of Science & Quality Council at American Urological Association
- NCI selects ATCC to provide end-to-end cancer epidemiology services
- ILO delays vote on whether to cut ties with tobacco industry
Drugs and Targets
- Kisqali gets FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
- Keytruda gets accelerated approval for classical Hodgkin lymphoma
- FDA extends Keytruda PDUFA date for microsatellite instability-high cancer
- Mylan announces settlement, license deals with Genentech and Roche on Herceptin
- Oncoceutics expands DRD2 research collaborations with NIH

Page 50 of 107« First «...10 20 30 40...46 47 48 495051 52 53 54 55...70 80 90 100...»Last »

Conversation with the Cancer Letter

Amy Abernethy: I want health IT companies to have an honest conversation about data sharing

Genentech’s rituximab SC received unanimous ODAC approval recommendation

In Brief

Drugs and Targets

Doug Lowy: We should continue to focus on the FY17 appropriation

Conversation with the Cancer Letter

Rick Klausner: This is a profoundly disturbing statement about dramatically de-prioritizing research, science, and biomedical research

Conversation with the Cancer Letter

Fran Visco: We should be partners on every level, not just when the NIH budget is threatened

In Brief

Drugs and Targets

Trump’s proposed 2018 budget launches a surprise attack on NIH

White House “vision” would cripple NIH

Conversation with the Cancer Letter

John Porter: If you want to make America great, you don’t take America’s worldwide scientific lead and cut it

Conversation with the Cancer Letter

Nancy Davidson: This is the time for investment, not for retreat

Conversation with the Cancer Letter

Ellen Sigal: This is not a grasstops issue anymore, this is really grassroots

Conversation with the Cancer Letter

Blase Polite: This was put together by folks who have no sense of how research is done

Conversation with the Cancer Letter

Patricia Goldsmith: This is the “Moonstab,” or, maybe, the “Moonshaft”

“Duplicity” at NIH?
White House spokesman Sean Spicer says the cut isn’t really a cut

Beth Caldwell: People like me will die because of these cuts

In Brief

Drugs and Targets